Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pract Radiat Oncol. 2017 Jan-Feb;7(1):63-71. doi: 10.1016/j.prro.2016.05.009. Epub 2016 Jun 3.
Fifteen fraction treatment schedules are increasingly used to deliver high doses of radiation therapy (RT) to both lung and hepatobiliary malignancies. The purpose of our study was to examine the incidence and predictors of chest wall (CW) toxicity in patients treated with this regimen.
We evaluated 135 patients treated with RT to doses ≥52.5 Gy in 15 fractions for thoracic and hepatobiliary malignancies between January 2009 and December 2012. We documented patient characteristics and CW dosimetric parameters for each case. Toxicity was scored using the Common Terminology Criteria for Adverse Events, version 4.0, criteria for radiation dermatitis and CW pain. Patient characteristics and CW dosimetric parameters were evaluated for their association with CW toxicity using proportional hazards regression.
Median follow-up was 9 months from the start of RT. Forty-eight patients (36%) developed dermatitis at a median time of 18 days. In multivariable analysis, the absolute volume of CW (in cm) receiving 40 Gy (V40) ≥120 cm was associated with the occurrence of dermatitis (hazard ratio, 3.12; 95% confidence interval, 1.74-5.60; P < .001). Twenty-one patients (16%) developed CW pain (20 grade 1, 1 grade 2) at a median time of 3 months. In multivariable analysis, CW V40 ≥150 cm was associated with the occurrence of CW pain (hazard ratio, 2.65; 95% confidence interval, 1.12-6.24; P = .03). The absolute rate of CW pain in patients with V40 <150 cm was 11% versus 26% in patients with V40 ≥150 cm (P = .03).
Hypofractionated RT with 15 fraction regimens results in an acceptable incidence of CW toxicity, specifically CW pain. We recommend a dose constraint of V40 <150 cm to minimize this adverse event.
十五分割治疗方案越来越多地用于向肺部和肝胆恶性肿瘤提供高剂量放射治疗(RT)。我们研究的目的是检查接受这种方案治疗的患者发生胸壁(CW)毒性的发生率和预测因素。
我们评估了 2009 年 1 月至 2012 年 12 月期间接受胸部和肝胆恶性肿瘤 RT 剂量≥52.5 Gy 的 135 例患者。我们记录了每位患者的特征和 CW 剂量学参数。使用通用不良事件术语标准,版本 4.0,评估毒性 ,用于放射性皮炎和 CW 疼痛。使用比例风险回归评估患者特征和 CW 剂量学参数与 CW 毒性的相关性。
从 RT 开始中位随访时间为 9 个月。48 例(36%)患者在中位时间 18 天出现皮炎。多变量分析中,CW 接受 40 Gy 的绝对体积(以 cm 为单位)(V40)≥120 cm 与皮炎的发生相关(危险比,3.12;95%置信区间,1.74-5.60;P<.001)。21 例(16%)患者在中位时间 3 个月时出现 CW 疼痛(20 级 1,1 级 2)。多变量分析中,CW V40≥150 cm 与 CW 疼痛的发生相关(危险比,2.65;95%置信区间,1.12-6.24;P=.03)。V40<150 cm 的患者 CW 疼痛的绝对发生率为 11%,而 V40≥150 cm 的患者为 26%(P=.03)。
15 分割方案的分次 RT 导致可接受的 CW 毒性发生率,特别是 CW 疼痛。我们建议将 V40<150 cm 的剂量限制作为最小化这种不良事件的方法。